In men with locally advanced/high-risk prostate cancer, there is an ongoing challenge to achieve improved results. Dose escalation studies using three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT) have shown benefit particularly in the intermediate and poor risk groups of patients. Of concern, however, is the increase in documented rectal toxicity. High-dose rate brachytherapy (HDR-BT) as a boost in combination with external beam radiotherapy (EBRT) is an alternative strategy of dose escalation that can potentially achieve an even higher biological equivalent dose (BED) to the tumour. The results so far are very encouraging for men with poor prognosis disease. Moreover the technique is associated with very low rates of acute and late toxicity.
Introduction
Prostate cancer is the most common cancer in men in the UK, accounting for one in five of newly diagnosed male cancers. Treatment options for early stage low risk disease might include active surveillance, radical prostatectomy, external beam radiotherapy (EBRT) or brachytherapy with 125 I seeds. D'Amico 1 has stratified men into three risk groups in an attempt to better identify the most effective treatment options (low risk ¼ stage T1c, T2a, and PSAp10 ng/ml and Gleason score p6, intermediate risk ¼ stage T2b or PSA410 and p20 ng/ml or Gleason score 7, high risk ¼ stage XT2c or PSA420 ng/ml or Gleason score X8). For men with locally advanced disease, or in whom there are factors associated with high-risk disease, there is emerging evidence that dose escalation with three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT) produces superior disease control. Dearnaley et al. 2 have looked at results of 5-year actuarial PSA control rates in patients who received the standard dose of 64 Gy compared with those escalated to 74 Gy. Patients receiving the conventional dose had 5-year control rates of 59 vs 71% in the patients who were treated to 74 Gy. Zelefsky et al. 3 have shown that increasing the dose delivered beyond 70.2 Gy in men with intermediate and high-risk disease improved the 5-year actuarial PSA relapse free survivals from 50 to 70 and 21 to 47%, respectively. Furthermore, this group of highrisk patients have shown a progressive reduction in positive biopsies at two or more years in these patients, with increasing dose. At the MD Anderson centre, Pollack and co-workers randomized patients to receive either 70 or 78 Gy. Their end point was the fraction of patients free from failure. In the group with PSA p10 ng/ml, no benefit from dose escalation was seen, with an average 6-year freedom from failure of 75%. However, in patients with PSA 410 ng/ml, the freedom from failure was 62% in the 78 Gy arm compared to 43% in the 70 Gy arm at 6 years. 4 This cohort had not undergone androgen deprivation. However, it is also worth noting that grade 2 or higher rectal toxicity rates increased from 12 to 26% in the 70 and 78 Gy groups, respectively.
An alternative method of dose escalation for patients with intermediate/high-risk disease (which can be defined for our purposes as those having two or more of stage T2b-T3b, presenting PSA410, Gleason score 46) is to offer HDR-BT with 192 Iridium in combination with a course of EBRT. The following is an outline of the technique, as performed at our institution, the rationale and the evidence available so far which points to excellent results within the context of high-risk disease.
Description of technique
Techniques tend to vary (in terms of number of insertions, fractionation and timing with EBRT) but the following briefly describes the procedure adopted at our centre. Patients are appropriately selected according to risk factors and fully informed and consented with regards to the procedure and potential side effects.
Treatment is an in-patient procedure requiring admission with bowel preparation a day prior to the procedure. Under anaesthetic, the patient is placed in the high lithotomy position. A Bi-Planar Ultrasound probe is inserted into the rectum and a template positioned on the perineum to provide a guidance system for needles insertion (see Figure 1 ) Needles are inserted into the prostate and surrounding tissues, including the seminal vesicles, under ultrasound control using the prior knowledge of distribution of disease within the gland and seminal vesicles. There is final optimisation of catheter positions using axial and sagittal ultrasound images (see Figures 2  and 3 ) and cystoscopy to insure that the catheters are covering the base of the prostate and causing tenting of, but not piercing, the bladder. The patient undergoes a planning CT scan and the prostate, seminal vesicles, rectum, urethra and bladder are outlined. An optimal plan is calculated which will dictate the dwell times of the iridium source at each position in each catheter (see Figure 4 , dose distribution diagram). Doses to the urethra and rectum are also calculated.
After an interval of 2 weeks, the second phase of treatment starts with EBRT as an outpatient.
Rationale for HDR brachytherapy
Conventionally, radiobiology states that the a/b ratios for tumours and normal late reacting tissue are 10 and 3, respectively. The a/b ratio describes the shape of the cell survival curve for individual tissues. Tissues which have a lower a/b ratio will undergo greater cell killing by larger doses per fraction of radiotherapy than tissues with a higher ratio. Normal late reacting tissue such as rectum is far more sensitive to the dose per fraction than tumour tissue. However, for prostate cancer, the emerging opinion is that the a/b ratio is in fact as low as 1.5. Recently, Bentzen and Ritter produced a very readable Challenge of dose escalation O Al-Salihi et al commentary on the subject, concluding that while the evidence does point towards high fractionation sensitivity for prostate cancer, there is still a need for more information from ongoing hypo-fractionation trials. 5 All this points to a strong radiobiological advantage from HDR-BT where large doses per fraction are given.
HDR-BT technique allows for the administration of a truly conformal and optimised treatment, which also takes account of organ movement. By allowing variation of source dwell times along the catheters there is greater control of dose received by the rectum and bladder and hence minimization of probability of acute and late toxicity to each. In addition, optimization of dose distribution across the target tissue is enabled with prior radiological and pathological data obtained. An example of this is knowledge of disease in the peripheral zone or seminal vesicles. Prostate volume is known to change after insertion of the catheters as a result of oedema. Although concern has been raised about the possible impact on dosimetry, given that fractionated treatment is given over two days, Kim et al. 6 have analysed this and have not found it to be of real significance. Hoskin et al. 7 have studied catheter movement between two fractions of HDR treatment and have found that although there is minimal change in prostate position between fractions, there is caudal migration of the catheters in relation to various landmarks, again due to the periprostatic oedema that develops. It is, therefore, important to able to quantify this movement over the period of treatment using appropriate imaging, and to be able to correct for it, thus maintaining an optimal plan.
From the patient's perspective, HDR-BT is very well tolerated. Finally, HDR-BT represents a true example of the use of multidisciplinary team talents and expertise across the fields of radiology, radiotherapy, surgery, physics and radiography.
The results of HDR brachytherapy
The most extensive experience and results have recently been pooled and analysed by Galalae, Martinez and Mate from Kiel, Michigan and Washington State, respectively. 8 Overall, 611 patients were pooled from the three institutions, treated between 1986 and 2000. The EBRT component of the treatment included the prostate, seminal vesicles and pelvic lymph nodes as the clinical target volume (CTV). The HDR-BT boost was performed during the course of the EBRT treatment. The dose per fraction varied between institutions, but at William Beaumont Hospital Michigan, there was dose escalation for two fractions from 5.5 to 11.5 Gy per fraction. Across the groups, the total biological equivalent dose (BED) for the combined treatment modalities ranged from 79.6 to 123 Gy 1.5 (assuming the a/b ratio for prostate to be 1.5).
In all, 70% of the patients were hormone naive and treated with radiotherapy only. In terms of risk stratification, 90% of patients had one or more of stage XT2b, Gleason score X7 and PSA X10.
Follow up ranged from 5 to 6.2 years. The 5-and 10-year results for biochemical control rates were 77 and 73%, and for overall survival 85 and 65%. Even in patients from the worst prognostic group (two or more of the above factors) the 5-year biochemical control rate reached 69%. This compares very favourably with data from Zelefsky et al. 3 looking at dose escalation and for whom the subgroup of patients with similar accumulation of high-risk factors, treated to doses between 75.6 and 86.4 Gy achieved a biochemical control rate of 47% at 5 years. The pooled analysis found no evidence of survival benefit from neoadjuvant/concurrent androgen deprivation therapy (ADT). However, patients were not randomized to ADT or no ADT and the limitations of this observation was acknowledged.
There are also encouraging results from other groups. Martin et al.
9 treated 102 patients with combination HDR-BT/ EBRT for which they achieved a BED of up to 107.6 Gy 1.5 . They classified 83% of their patients as being in an unfavourable risk group (having on or more of stage T3, WHO grade 3 and pre-treatment PSA410 ng/ml). In addition, they integrated neoadjuvant/adjuvant androgen deprivation into their treatment. Their actuarial biochemical control rates at 2 and 3 years were 87 and 82%, respectively. Pellizzon et al. 10 achieved similarly good biochemical control, in a mixed group of 119 patients, of up to 75.3% at 4 years. Hiratsuka et al.
11 treated 71 patients in whom 56% had 42b stage disease, 65% had initial PSA410 ng/ml and 37% had Gleason score X7 with a BED of up to 88.2 Gy 1.5 . Of interest, hormonal therapy was given prior to, but not during treatment, and in their later cohort of patients, the EBRT was given to the prostate only, but with staging pelvic lymphadenopathy being performed in high-risk patients to rule out N1 disease. This group achieved a biochemical control rate of 93% at 5 years. For further information about results from other groups and an analysis of the variation in treatments administered, we recommend referring to an excellent recent overview by Morton. 12 Toxicity data from HDR-BT has been well documented. Mate et al. 13 recorded that the most common late complication in their patients was the development of urethral stricture. The mean time of onset was 27 months post therapy. Their projected stricture rate was 8% at 5 years. These strictures have been managed successfully by urethral dilatation or limited urethrotomies. When analysing this further, they found that modification of technique served to reduce stricture formation and the only risk factor documented seemed to be prior TURP. Rectal toxicity was very infrequent, being documented in only two out of 104 patients as recurrent intermittent bleeding and further colonoscopy revealed minor radiation proctitis.
In their analysis of late toxicity 14 Martinez et al. noted that 10 out of 207 patients had developed urethral stricture. On further analysis, it appeared that the main predictor for stricture formation was three as opposed to two separate implant procedures. The other main toxicity was sexual impotence, which was seen at a median of 2.3 years in 51% of patients. This is similar to the rate seen in men treated with EBRT alone.
Galalae et al. 15 also reported on late morbidity in their results of HDR brachytherapy. They found a significant risk of development of urinary incontinence in patients who had received a TURP in a short period before or after treatment (eight out of 144 patients). In addition, four patients developed urethral stricture and four had developed bladder sphincter sclerosis. Again these patients had undergone TURP with a mean interval leading up to radiotherapy of approximately 5 months. As
Challenge of dose escalation O Al-Salihi et al a result of these findings, they recommend a time gap of at least 6 months between TURP and therapy and found no further incidence of these toxicities in subsequent patients.
Conclusion
HDR-BT in combination with EBRT provides a means of treatment which can achieve a superior level of BED in a group of patients with locally advanced/high-risk prostate cancer for whom there is excellent evidence of benefit from dose escalation therapy. Combined with EBRT, HDR-BT draws on experience from many specialities working together in a multi disciplinary fashion to produce a truly conformal and optimised treatment modality in which dose escalation can be tailored to each patient's individual pathology and disease distribution. Moreover, with emerging evidence that prostate cancer appears more sensitive to dose fractionation, it is a means of providing hypo-fractionation as part of the overall treatment without a significant increase in rectal toxicity. Urethral stricture is the main additional complication seen above and beyond those, which occur with EBRT alone. It is amenable to simple dilatation and its incidence can be reduced by limiting the dose received by the urethra.
